Products for Research Use Only

BRD4-IN-11

CAT: 0804-HY-175033Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-175033Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BRD4-IN-11 is an orally active and selective BRD4 inhibitor (IC50 = 26.35 nM (BD1), IC50 = 72.81 nM (BD2) ) . BRD4-IN-11 is approximately 3- to 18-fold more potent against BRD4 than againstBRD2, BRD3, and BRDT. BRD4-IN-11 enhances H2S release and inhibits the upregulation of fibrotic markers (α-SMA and fibronectin), c-Myc, and CDC25B. BRD4-IN-11 reduces apoptosis in LO2 hepatocytes. BRD4-IN-11 significantly improves liver and lung function in a hepatopulmonary fibrosis model and can be used to study hepatopulmonary fibrosis[1].
UNSPSC
12352005
Target
Apoptosis; c-Myc; Epigenetic Reader Domain; Phosphatase
Related Pathways
Apoptosis; Epigenetics; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
CC1=NN=C2[C@@H](N=C(C3=C(N12)SC(C)=C3C)C4=CC=C(C=C4)Cl)CC(OC5=CC=C(C=C5)OCCCCCCOC6=CC=C(C=C6)C7=CC(SS7)=O)=O
Molecular Formula
C40H37ClN4O5S3
Molecular Weight
785.39
References & Citations
[1]Zhu Y, et al. Design, synthesis, and biological evaluation of a dual-action agent targeting bromodomain and extraterminal domain and H2S release for the treatment of hepatic and pulmonary injury. Eur J Med Chem. 2025 Oct 15;296:117887.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4

Popular Products